53.9 F
San Diego
Tuesday, Jan 31, 2023
-Advertisement-

Ignyta Ends Development of 3 Potential Cancer Treatments, Dismisses Chief Science Officer

San Diego’s Ignyta Inc. is ending development of three potential cancer treatments — two of them acquired from Teva Pharmaceutical Industries — to focus on more promising candidates.

In a statement, Ignyta said it will concentrate on candidates that have generated the most promising results, while deprioritizing pipeline programs that have either generated less promising data or fall outside of Ignyta’s focus on molecularly targeted therapies.

Being tossed by Ignyta are the Phase 1 candidate RXDX-107 and two preclinical treatments, RXDX-103 and RXDX-108. Ignyta acquired RXDX-107 and RXDX-108, as well as two other cancer candidates, from Teva last year in a deal valued at $15 million.

Two other candidates — RXDX-105 and RXDX-106 — are among four experimental cancer treatments Ignyta said it will continue developing.

- Advertisement -

Ignyta will also be discontinuing some of its “Spark” discovery programs.

In a regulatory filing, the company also disclosed that it was terminating Robert Wild, its chief science officer and senior vice president of research, in connection with its refocusing of research.

“After reviewing our pipeline and recent preclinical data for certain programs in light of this goal, and keeping in mind our obligation to be good stewards of our resources, we are undertaking this streamlining of our operations to focus on the key priorities and competencies that we believe are most likely to generate value for patients and stockholders,” Dr. Jonathan Lim, Ignyta’s chairman and CEO, said in a statement.

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-